The high MDM2 levels needed to drive MYCN expression exceed those needed to suppress p53-mediated apoptosis and thus abrogate the need for genomic inactivation of p53-mediated tumor surveillance signaling in retinoblastoma and neuroblastoma tumors (16, 17). The gene discussed is MYCN; the disease is retinoblastoma.